Swiss Semiconductors Stock News

Roche Holding (SWX:ROP) has received FDA Priority Review for giredestrant as an adjuvant therapy in ER-positive, HER2-negative early-stage breast cancer. The filing is supported by phase III lidERA data, which showed a significant improvement in disease-free survival compared with current standard-of-care endocrine therapy. The Priority Review focuses on use of giredestrant after surgery, where adjuvant options have seen limited change for more than two decades. Roche is a large global...

Why Partners Group’s redemption cap matters for shareholders Partners Group Holding (SWX:PGHN) has limited withdrawals from its $8.6b evergreen private equity fund to 5% of net asset value per quarter after redemption requests reached an estimated 9.8% in the second quarter. The stock has come under pressure, with shares down about 18% over the past month and roughly 31% year to date, as investors reassess liquidity risks and the business impact of tighter fund gates. See our latest analysis...

Tecan’s India move and what it means for the stock Tecan Group (SWX:TECN) has launched direct operations in India, setting up a local sales and service team in Gurugram and formalizing Tecan India as part of its broader regional expansion. This step follows the company’s move into South Korea in 2024 and gives Tecan closer access to pharmaceutical, biotechnology, academic and diagnostic customers in one of the fastest growing life sciences markets. See our latest analysis for Tecan Group. The...

As European markets navigate the complexities of geopolitical developments and economic adjustments, the pan-European STOXX Europe 600 Index shows modest gains, reflecting investor optimism amid global uncertainties. With this backdrop, dividend stocks in Europe present a compelling opportunity for investors seeking stable income streams; these stocks are often characterized by strong fundamentals and consistent payout histories that can provide resilience in fluctuating market conditions.

ABB (SWX:ABBN) has integrated its power systems as SimReady 3D digital assets into NVIDIA's Omniverse DSX Blueprint. The partnership focuses on virtual modeling, validation, and optimization of data center power distribution for AI workloads before facilities are built. The announcement extends ABB's digital twin and AI infrastructure offering for large scale, energy focused data centers. ABB comes into this announcement with the share price at CHF86.1 and very strong recent returns,...

As European markets show cautious optimism amid geopolitical developments and economic adjustments, investors are increasingly focused on identifying growth opportunities with strong fundamentals. In this context, companies with high insider ownership often attract attention as they may indicate a strong alignment of interests between management and shareholders, potentially offering resilience in uncertain market conditions.

Shareholders appeared to be happy with LEM Holding SA's ( VTX:LEHN ) solid earnings report last week. This reaction by...

Novartis (SWX:NOVN) reported long term clinical data for Scemblix showing sustained superior efficacy and a favorable safety profile in chronic myeloid leukemia. The company also released expanded clinical evidence for Pluvicto in prostate cancer, underscoring progress in its radioligand therapy franchise. These data come from pivotal clinical trials and mark important milestones for Novartis in hematology and oncology. For investors tracking large pharma, these updates touch two core...

Landis+Gyr Group (SWX:LAND) is back on investors’ radar after its 2026 Capital Markets Day in New York, where the company outlined new Connected Platforms and Grid Intelligence segments and reaffirmed mid term growth expectations through 2028. See our latest analysis for Landis+Gyr Group. The CHF52.0 share price has seen a 4.31% 1 day share price return around the Capital Markets Day update, while the 1 year total shareholder return of 3.27% contrasts with a decline over the 3 year period of...

Roche Holding (SWX:ROP) is back in focus after a string of late May and early June product updates in obesity treatments and oncology, including fresh U.S. regulatory decisions and new clinical data presentations. See our latest analysis for Roche Holding. Despite the flurry of obesity and oncology updates, momentum in the shares has eased, with the 90 day share price return down 13.68% and the year to date share price return down 4.85%, even as the 1 year total shareholder return stands at...

Recent performance snapshot Idorsia (SWX:IDIA) has attracted fresh attention after a strong rebound over the past year, with the stock up about 166% over that period and showing gains across the past month and past 3 months. For investors tracking shorter time frames, Idorsia shares are up about 6% over the past week and around 19% over the past month, while the past 3 months show a gain of roughly 8%. See our latest analysis for Idorsia. Putting it together, Idorsia’s recent 1-day share...

Dätwyler Holding AG ( VTX:DAE ), is not the largest company out there, but it saw a double-digit share price rise of...

Recent share performance and business profile Compagnie Financière Tradition (SWX:CFT) has drawn investor attention after recent trading, with the stock last closing at CHF 268. The move comes against a mixed pattern of short and longer term returns. Over the past month the share price declined about 9%, and it is down roughly 2% over the past 3 months and 6% year to date. In contrast, the 1 year total return is about 23%, with very large gains over the past 3 and 5 years. The company...

As European markets experience modest gains, with the pan-European STOXX Europe 600 Index advancing slightly and major indices like Germany’s DAX and France’s CAC 40 showing positive movement, investors are keenly observing geopolitical developments that could impact energy markets. In this context, dividend stocks can offer a measure of stability and income potential; they are particularly appealing when market conditions are uncertain or volatile.

Galenica (SWX:GALE) confirmed its 2026 guidance and reiterated expectations for sales growth of 5% to 7% and EBIT growth of 6% to 8%, keeping investor attention on its earnings outlook. See our latest analysis for Galenica. The confirmation of 2026 guidance comes after a period where the share price has lost some momentum. The 90 day share price return is down 12.45% and the year to date share price return is down 15.29%, even as the 5 year total shareholder return of 49.84% points to more...

Nestlé (SWX:NESN) is back in focus after Nestlé Health Science agreed a licensing deal with IdB Holding S.p.A. to develop and commercialize VOWST in Europe, pending approval from the European Medicines Agency. See our latest analysis for Nestlé. The VOWST licensing deal lands at a time when Nestlé’s share price, at CHF79.44, has edged higher year to date, but its 1 year total shareholder return is still down, signalling that longer term momentum has been weak even as recent news shifts...

Recent share performance and basic snapshot Novartis (SWX:NOVN) has seen mixed share performance recently, with the stock down over the past week but higher over the past month, and its total return over the past year above 25%. The company has a market value of about CHF 224.8b, with revenue of $56,578.0m and net income of $13,534.0m from its pharmaceutical operations across cardiovascular, immunology, neuroscience, oncology, and hematology therapies. See our latest analysis for Novartis. At...

UBS Group (SWX:UBSG) is proceeding with significant job cuts as it integrates Credit Suisse into its global operations. The company is restructuring its combined workforce to streamline overlapping functions and adjust its operating model. The Federal Reserve has formally ended enforcement actions against both UBS and Credit Suisse, closing a long running regulatory chapter. These developments arrive as UBS continues its multi year integration process following the Credit Suisse...

As global markets navigate a landscape marked by inflation concerns, geopolitical tensions, and fluctuating consumer sentiment, investors are keenly observing shifts in stock indices. With the Dow Jones Industrial Average reaching an all-time high and small-cap stocks outperforming their larger counterparts, opportunities to identify undervalued stocks have become increasingly appealing. In this environment, a good stock is often characterized by strong fundamentals that may not yet be fully...

Shareholders will be ecstatic, with their stake up 38% over the past week following LEM Holding SA 's ( VTX:LEHN...

ABB (SWX:ABBN) has drawn fresh attention after three closely timed developments, including the launch of its IE6 Hyper Efficiency motor for hazardous areas, a compact high power ACS580 R9e drive, and a new industrial AI collaboration with Cognite. See our latest analysis for ABB. These product launches and the Cognite industrial AI collaboration arrive while momentum in ABB's stock has been building. The 30 day share price return of 7.81% and the 1 year total shareholder return of 79.53%...

The market for Ypsomed Holding AG's ( VTX:YPSN ) stock was strong after it released a healthy earnings report last...

UBS Group (SWX:UBSG) has drawn attention after a golden cross, where its 50 day moving average moved above the 200 day level. This technical event coincided with a stronger earnings outlook and upward earnings estimate revisions. See our latest analysis for UBS Group. Recent momentum has been strong, with a 1 day share price return of 0.89%, a 30 day share price return of 15.0%, and a 1 year total shareholder return of 44.74%. This suggests sentiment has shifted positively around UBS...

Adecco Group (SWX:ADEN) is back in focus after being placed on the Zacks Rank #5 (Strong Sell) list, following a 9% cut to consensus earnings estimates over the past two months. See our latest analysis for Adecco Group. Despite a 1-day share price return of 1.22% taking Adecco Group to CHF15.76, the 30-day share price return is down 10.86% and the 1-year total shareholder return has fallen 28.60%. This suggests momentum has faded even after Q1 earnings growth and an executive committee change...